Amylin and amylin agonists for treating psychiatric diseases and disorders
View Patent ↗Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
1. A method for treating depression in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:6 to treat the depression.
2. The method of claim 1 , wherein the peptide is administered parenterally.
3. The method of claim 1 , further comprising administering to the human a therapeutically effective amount of: (i) a tricyclic antidepressant, (ii) a monoamine oxidase inhibitor, (iii) a selective serotonin reuptake inhibitor, (iv) a serotonin and noradrenaline reuptake inhibitor, or (v) a combination of two or more thereof.
4. A method for treating a major depressive disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:6 to treat the major depressive disorder.
5. The method of claim 4 , Wherein the peptide is administered parenterally.
6. The method of claim 4 , further comprising administering to the human a therapeutically effective amount of: (i) a tricyclic antidepressant, (ii) a monoamine oxidase inhibitor, (iii) a selective serotonin reuptake inhibitor, (iv) a serotonin and noradrenaline reuptake inhibitor, or (v) a combination of two or more thereof.
7. A method for treating depression in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:6 to treat the depression.
8. The method of claim 6 , wherein the peptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6.
9. The method of claim 6 , wherein the peptide is administered parenterally.
10. The method of claim 7 , further comprising administering to the human a therapeutically effective amount of: (i) a tricyclic antidepressant, (ii) a monoamine oxidase inhibitor, (iii) a selective serotonin reuptake inhibitor, (iv) a serotonin and noradrenaline reuptake inhibitor, or (v) a combination of two or more thereof.
11. A method for treating a major depressive disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:6 to treat the major depressive disorder.
12. The method of claim 11 , wherein the peptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6.
13. The method of claim 11 , wherein the peptide is administered parenterally.
14. The method of claim 11 , further comprising administering to the human a therapeutically effective amount of: (i) a tricyclic antidepressant, (ii) a monoamine oxidase inhibitor, (iii) a selective serotonin reuptake inhibitor, (iv) a serotonin and noradrenaline reuptake inhibitor, or (v) a combination of two or more thereof.